Legend Biotech Corporation
LEGN
Rang in Aktien
#4424
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Aktienkurs
$19.04
Marktkapitalisierung
$3.52B
Veränderung (1 Tag)
2.09%
Veränderung (1 Jahr)
-42.15%
Land
US
Handel Legend Biotech Corporation (LEGN)
Kategorie
Healthcare
Aktien-Split-Historie für Legend Biotech Corporation (LEGN)
Die Aktie Legend Biotech Corporation (Symbol: LEGN) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Oct 20, 2026 statt.
Eine LEGN-Aktie, die vor dem Oct 20, 2026 gekauft wurde, entspricht heute 0 LEGN-Aktien.
Der letzte Aktiensplit fand am Oct 20, 2026 statt.
Eine LEGN-Aktie, die vor dem Oct 20, 2026 gekauft wurde, entspricht heute 0 LEGN-Aktien.
Liste der Aktiensplits
| Jahr | Aktien-Split | Multiplikator | Kumulierter Multiplikator |
|---|---|---|---|
| Nicht genügend Daten für die angegebenen Daten. | |||
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
| Unternehmen | Anzahl der Aktiensplits | Kumulierter Multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
